Diagnosis and management of tardive dyskinesia: from research to clinical practice
Rivista di Psichiatria · 2025
DOI: 10.1708/4487.44874 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rivista di Psichiatria, 2025. Verfasst von Andrea Fagiolini und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Siena, Italy. Hauptthemen laut MEDLINE: Tardive Dyskinesia, Antipsychotic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Tardive dyskinesia (TD) is a chronic, often disabling hyperkinetic movement disorder associated with prolonged use of dopamine receptor blocking agents (DRBAs), particularly antipsychotics (APs) for psychiatric disorders such as schizophrenia and bipolar disorder. It manifests as abnormal, involuntary movements, often involving the orofacial region, extremities, or trunk, and is associated with significant physical and psychosocial impairment. TD is primarily linked to dopamine receptor hypersensitivity, oxidative stress, and genetic susceptibility, with a higher prevalence in patients treated with first-generation APs. However, second-generation APs (SGAs) have not eliminated the risk entirely, particularly in older adults and those with prolonged exposure. Diagnosis relies on clinical assessments such as the Abnormal Involuntary Movement Scale (AIMS) and comprehensive neurological evaluations. Treatment guidelines emphasize early detection, prevention through minimal effective doses of APs, and the use of VMAT2 inhibitors (vesicular monoamine transporter 2 inhibitors) as a first-line therapy in moderate-to-severe cases. VMAT2 inhibitors reduce dopamine signaling dysregulation without directly blocking D2 receptors, effectively managing symptoms in many patients. For treatment-resistant cases, deep brain stimulation and other non-pharmacological interventions offer promising alternatives. Current research underscores the complexity of TD’s pathophysiology and the need for personalized approaches. Future directions include developing biomarkers for risk stratification, refining therapeutic strategies, and optimizing long-term outcomes through multidisciplinary care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Siena, Italy.
- Department of Neurology, University of Salerno, Italy.
- Department of Clinical and Experimental Medicine, University of Foggia, Italy.
- Department of Mental Health, ASST Bergamo, Italy.
- Department of Neurology, Santa Maria Hospital, Terni, Italy.
- Department Human Neurosciences, Sapienza University of Rome and IRCCS Neuromed.
Zitieren
APA
Fagiolini, A., Barone, P., Bellomo, A., Bondi, E., Colosimo, C., Fabbrini, G., Maina, G., Pompili, M., Tinazzi, M., Vita, A., & Cuomo, A. (2025). Diagnosis and management of tardive dyskinesia: from research to clinical practice. Rivista di Psichiatria. https://doi.org/10.1708/4487.44874
Vancouver
Fagiolini A, Barone P, Bellomo A, Bondi E, Colosimo C, Fabbrini G, et al. Diagnosis and management of tardive dyskinesia: from research to clinical practice. Rivista di Psichiatria. 2025. doi:10.1708/4487.44874
BibTeX
@article{Fagiolini2025,
author = {Fagiolini, Andrea and Barone, Paolo and Bellomo, Antonello and Bondi, Emi and Colosimo, Carlo and Fabbrini, Giovanni and Maina, Giuseppe and Pompili, Maurizio and Tinazzi, Michele and Vita, Antonio and Cuomo, Alessandro},
title = {Diagnosis and management of tardive dyskinesia: from research to clinical practice},
journal = {Rivista di Psichiatria},
year = {2025},
doi = {10.1708/4487.44874}
}
EUVIMED